Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

iCardiac adds $2m to series A:

This article was originally published in Clinica

Executive Summary

Rochester, New York-based iCardiac Technologies has brought the total raised in a series A financing to $4m, after receiving an additional $2m in an investment round led by Advantage Capital Partners and Stonehenge Capital Company. The proceeds will be used "to meet the increased interest in its technology by the pharmaceutical and biotechnology industries", says iCardiac's CEO, Mikael Totterman. The company is developing cardiac safety analysis technologies that can be used for assessing the safety profile of cardiac drugs, as well as for ECG-based cardiac diagnostic and medical device applications.

You may also be interested in...



J&J Leverages Power Of Digital Personalization With Nicorette UK Extension

Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.

Bio-Thera Ventures Outside China With European Bevacizumab Filing

China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel